Shuda Scott
Shuda Scott's purchase track record
Shuda Scott has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/24/2025 | IRIX | $26K | +13.8% | -6.0% | +22.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
IRIX Completes Move of Manufacturing Facility to San Jose. Iridex has finished moving its manufacturing operations to a new facility in San Jose, California. The relocation may affect the company's production schedule as it adjusts to the new site. Investors may watch how the transition influences operating costs and supply chain efficiency.
Transaction History
| INFU | ▼ Sell | Other | 20,000 | $0 | 9/10/2026 | View on chart |
| INFU | ▼ Sell | Open Market | 5,752 | $56K | 8/22/2025 | View on chart |
| INFU | ▼ Sell | Other | 2,242 | $0 | 7/7/2025 | View on chart |
| IRIX | ▲ Buy | Open Market | 21,457 | $26K | 4/24/2025 | View on chart |
| INFU | ▼ Sell | Other | 42,241 | $0 | 12/5/2024 | View on chart |
| INFU | ▲ Buy | Option Exercise | 35,000 | $165K | 5/14/2024 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 23,500 | $165K | 5/14/2024 | View on chart |
| IRIX | ▲ Buy | Grant | 39,267 | $75K | 6/14/2023 | View on chart |
| INFU | ▲ Buy | Option Exercise | 25,000 | $80K | 9/16/2022 | View on chart |
| IRIX | ▲ Buy | Grant | 27,472 | $0 | 6/15/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 25,000 | $50K | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
INFU Shares Business Overview, Emphasizes Patient-First Strategy
INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.
INFU Shares Business Overview, Emphasizes Patient-First Strategy. INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.